Trial Search Results

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

This study is being conducted to compare the effects of a 91-day oral contraceptive (OC) to a 28-day OC regimen on bone mineral density (BMD) in adolescent females.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Duramed Research

Stanford Investigator(s):


  • Drug: 91-day Levonorgestrel Oral Contraceptive
  • Drug: 28-day Levonorgestrel Oral Contraceptive


Phase 2


Inclusion Criteria:

   - Healthy postmenarchal adolescent female 12-18 years old, non-pregnant, nonlactating

   - Regular spontaneous menstrual cycles

   - Body mass index (BMI): 18 kg/m² to <30 kg/m², weight < 200 lbs

   - Others as dictated by the Food and Drug Administration (FDA)-approved protocol

Exclusion Criteria:

   - Any contraindication to the use of oral contraceptives

   - History of previous clinically significant adverse event while taking hormonal

   - Use of any medication which could significantly interfere with study assessments

   - Others as dictated by FDA-approved protocol

Ages Eligible for Study

12 Years - 18 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kelsey Lynd
Not Recruiting